Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
L1CAM-specific CAR T cells for SCNPC
NCT06094842Phase 1Withdrawn
- Sponsor
- Fred Hutchinson Cancer Center
- Start
- Apr 2025
- Primary completion
- Mar 2028
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of L1CAM-specific CAR T-cells in small cell neuroendocrine carcinoma of the prostate (SCPC), sponsored by Fred Hutchinson Cancer Center. Primary endpoints: Incidence of adverse events up to 12 months and Dose-limiting toxicity rates at 28 days. Planned start Apr 2025; status: withdrawn.
02
Drugs
L1CAM-specific CAR T-cells
03
Conditions
small cell neuroendocrine carcinoma of the prostate (SCPC)
Beyond the preview
Go deeper on NCT06094842.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06094842.